Ken Griffin’s Citadel Investment Group Boosts Stake in William Lyon Homes (WLH)

Ken Griffin‘s Citadel Investment Group has significantly raised its exposure to William Lyon Homes (NYSE:WLH), a new filing revealed. Citadel disclosed owning over 1.40 million class A shares of the company, versus 905,500 shares held previously. The new stake amasses 5.1% of the company’s class A stock.


Earlier, Christian Leone’s Luxor Capital Group reported selling a total of 2.3 million shares of William Lyon Homes (NYSE:WLH) in a public offering for a price of $27.25 apiece. Following the sale, Luxor holds 6.29 million shares of the company, which represent 23% of the class A stock.

For the past year, William Lyon Homes (NYSE:WLH), a company engaged in the design and construction of single family houses, reported a net income of $4.95 per diluted share, versus a loss of $0.93 posted a year earlier. Moreover, the company’s revenue also went up to $572.5 million, from around $398 million reported for 2012.

Several other investors hold shares of William Lyon Homes (NYSE:WLH) according to the latest round of 13F filings. John Paulson‘s Paulson & Co held 3.32 million shares, valued at $67.51 million. Followed by  Tom Brown‘s Second Curve Capital, and Robert Bishop‘s Impala Asset Management, which held 3.32 million and 1.24 million shares, up by 27% and 22% over the quarter respectively.

Last month, Ken Griffin raised his position in Arch Coal Inc (NYSE:ACI) to 11.6 million shares, from 160,100 shares. The new stake amasses 5.4% of the common stock. The largest position in Ken Griffin’s equity portfolio is held by Apple Inc. (NASDAQ:AAPL), in which the fund owns over 1.59 million shares, valued at $894.14 million.

Disclosure: none

Recommended Reading:

Ken Griffin and Citadel Are Bullish on Veeva Systems Inc (VEEV)

Billionaire Ken Griffin’s New Stock Moves

Citadel Advisors’ Two Latest Moves: ChannelAdvisor Corp (ECOM) and KB Home (KBH)

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!